ST Robotics Reports They Are Increasing Their Laboratory Robotics Production to Meet Demand from COVID-19

Today ST Robotics reported they are ramping up its shipments of four, five and six-axis industrial robots, in response to the recent increase in demand from COVID-19.

ST Robotics notes that Mesa Labs in Montana is using the ST Robotics systems to increase production and maximize flexibility for the vapor hydrogen peroxide sterilization of its Apex biological indicator (BI) products.  To meet their client demands in the fight against COVID-19, Mesa Labs is in the process of implementing another ST robotic arm that is specifically designed for a medical device manufacturer of personal protective equipment (PPE).

“By using ST Robots, we save 22 hours of direct labor per day.   ST Robotics is wonderful to work with and their products have been a great investment for our product lines,” commented Nicholas Spain, Mesa Labs Senior Manager of Manufacturing.

ST Robotics has been a successful producer in laboratory robotics since 1993.  Their customers include major pharmaceutical companies and research institutes, including the National Institutes of Health (NIH), the Wellcome Sanger Institute, Pfizer, GlaxoSmithKline (GSK), and Eli Lilly.  ST Robotics improves the automation of everything from polymerase chain reaction (PCR) to high-throughput screening in forensic science, drug development, bacterial resistance, toxicology, stem cell research, and other fields.  The UK Forensic Science Service set up the largest national DNA database in the world using eight ST robots.

“Even today, we are still able to solve those difficult laboratory automation problems that no-one else can solve,” says David Sands, Founder CEO at ST Robotics. “Moreover, because of our vast experience in the demanding world of manufacturing, we can offer the lab market a totally reliable workhorse of a robot, together with software and hardware that enables us to interface with any other instruments or devices.”  Sands also founded the European branch of the Laboratory Robotics Interest Group (ELRIG) in 2001.

According to a new report by Market Watch, The Global Lab Automation Market is expected to exceed more than US$ 8 Billion by 2027 at a CAGR of 6.5%.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”